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Abstract
p53 and p73 interact with human papillomavirus (HPV) E6 and E7 oncoproteins. The interplay between p53 and p73 and
HPV16 may lead to deregulation of cell cycle and apoptosis, through which inflammation/immune responses control the
HPV clearance and escape of immune surveillance, and subsequently contribute to tumor HPV16 status. In this case-case
comparison study, HPV16 status in tumor specimens was analyzed and p53 codon 72 and p73 G4C14-to-A4T14
polymorphisms were genotyped using genomic DNA from blood of 309 oropharyngeal cancer patients. Odds ratios (ORs)
and 95% confidence intervals (95% CIs) were calculated in univariate and multivariable logistic regression models to
examine the association. The results from this study showed both p53 variant genotypes (Arg/Pro+Pro/Pro) and p73 variant
genotypes (GC/AT+AT/AT) were significantly associated with HPV16-positive tumor in oropharyngeal cancer patients (OR,
1.9, 95% CI, 1.1–3.3 and OR, 2.1, 95% CI, 1.2–3.8, respectively), while the combined variant genotypes (p53 Pro carriers and
p73 AT carriers) exhibited a significantly greater association with HPV16-positive tumor (OR, 3.2, 95% CI, 1.4–7.4), compared
with combined wild-type genotypes (p53 Arg/Arg and p73 GC/GC), and the association was in a statistically significant dose-
effect relationship (p=0.001). Moreover, such association was more pronounced among several subgroups. These findings
suggest that variant genotypes of p53 and p73 genes may be individually, or more likely jointly, associated with tumor
HPV16-positive oropharyngeal cancer patients, particularly in never smokers. Identification of such susceptible biomarkers
would greatly influence on individualized treatment for an improved prognosis.
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Introduction
Squamous cell carcinoma of the head and neck (SCCHN)
typically presents in advanced stages and is associated with poor
survival and high recurrence and second primary tumor rates [1].
Tobacco smoking and alcohol drinking are still the primary risk
factors for SCCHN [2], but the incidence of oropharyngeal cancer
is increasing especially in patients who are not smokers and alcohol
abusers [3,4], attributed mainly to the human papillomavirus
(HPV). The absolute survival rates with chemoradiotherapy, a
popular treatment approach for oropharyngeal cancers, have
remained modest [5], whereas advanced oropharyngeal cancers
appear to benefit from minimally invasive surgical approaches plus
adjuvant therapy [6]. Several studies have compared the survival
between HPV-negative patients and HPV-positive patients (chiefly
oropharynx patients) [7–11], but the impact of HPV-positivity on
survival is inconsistent. Therefore, further studies are needed to
understand susceptibility for and modifying factors of the HPV16
carcinogenic process, which will facilitate individualized treatment
for oropharyngeal cancers.
The prognosis for oropharyngeal cancer patients is in part
explained by current staging and imaging techniques, while an
identification of HPV associated oropharyngeal cancer may have
important prognostic implications. Although HPV tumor positivity
confers a favorable outcome, independent of other significant
confounding factors including stage, treatment, smoking, etc,
HPV-positive cancers are more likely to have a later stage, nodal
involvement and advanced grade compared to HPV-negative
cancers [12]. These facts may promote consideration for a new
staging system for oropharyngeal cancer, stratified by HPV status.
Thus, identification of new biomarkers for tumor HPV status
detection (e.g., HPV DNA in tumors) may help ensure appropriate
therapy for a better clinical outcome.
Both p53 and p73 can be activated by oncogenic signals, such as
those derived from HPV DNA genome integration in the nucleus
of host cells, to regulate cell cycle control and apoptosis [13–16].
High-risk oncogenic HPV16 accounts for approximately 90% of
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malignant transformation through its E6 and E7 oncoproteins
[19], and inactivation of both p53 and p73 by E6 allows the cell to
escape normal cell cycle checkpoints, leading to cell transforma-
tion and immortalization [19–21].
p53 codon 72 polymorphism causes a change in the p53 protein
sequence with a substitution of proline for arginine at codon 72,
which may alter the apoptotic potential of p53 and the
susceptibility of p53 to E6-mediated degradation [22–24], and
subsequently affect the carcinogenic potential of HPV16. p73
G4C14-to-A4T14 polymorphism at exon 2 appears to result in an
alteration of gene expression possibly by altering the efficiency of
translational initiation [25]. Such alteration in p73 expression may
also influence on the interaction between E6 protein and p73 and
its apoptotic capacity [26]. Thus, each of these genetic variants
may affect the interaction between p53 and p73 and HPV, and
result in individual differences in resistance to apoptosis, which
might enable HPV-infected cancer cells to escape or counterattack
against the inflammation/immune responses. Therefore, such
genetic variants may affect HPV clearance, subsequently contrib-
uting to tumor HPV16 status of oropharyngeal cancer patients.
Since p53 and p73 variants can alter the affinity for or functional
interactions of the E6 protein with both p53 and p73, they may
jointly affect the association between tumor HPV16 status and
these two polymorphisms. To test the hypothesis, the combined
effect of these two putatively functional polymorphisms of p53 and
p73 on the association was analyzed in this case-case comparison
study of 309 newly diagnosed oropharyngeal cancer patients for
whom tumor specimens became available.
Materials and Methods
Study Subjects
In this study, a total of 309 oropharyngeal cancer patients were
enrolled consecutively as part of an ongoing molecular epidemi-
ology study of SCCHN at The University of Texas M. D.
Anderson Cancer Center from December 1996 to November
2009. Details for recruitment of study patients have been
previously described [27]. Briefly, these patients were recruited
before treatment without restrictions on age, sex, and cancer stage,
and all cases were newly diagnosed and histologically confirmed
oropharyngeal squamous cell carcinoma. A total of 30 ml of blood
was drawn from all these patients for the genotyping. Paraffin-
embedded tumor tissue samples were requested for tumor HPV16
detection. In addition, all of the patients signed informed consent
and completed a questionnaire. The protocol of this study was
reviewed and approved by the University of Texas M.D. Anderson
Cancer Center institutional review boards.
Tumor HPV16 Detection
The DNA from the paraffin-embedded tumor tissues of all study
patients was extracted using a tissue DNA extraction kit (Qiagen
Inc., Valencia, CA). Tumor tissues from the study subjects were
tested for the presence of HPV16 DNA using PCR-based type-
specific assays with modification and quality control for the E6 and
E7 regions [28]. Assays of the samples were run in triplicate, with
positive (Siha cell line) and negative (TPC-1 cell line) controls and
with b-actin as DNA quality control. Each subject was classified as
HPV16-positive or HPV16-negative based on tumor HPV16
DNA determination. Southern blotting analysis was performed to
confirm HPV16 E6 and E7 specificity in a portion of the paraffin-
embedded tissue samples, using a Roche Diagnostics labeling and
hybridization system [3] (Roche Applied Science, Indianapolis,
IN). HPV16 E6 and E7 specificity were also confirmed in a
portion of samples by digesting the PCR products with restriction
enzymes Ban II and Msp I to verify the specific fragments for E6
and E7. The results of the two methods were 100% concordant.
The results of tumor HPV16 status were confirmed with 100%
concordance in the repeated samples.
p53 and p73 Genotyping
p53 and p73 polymorphisms were genotyped using genomic
DNA which was isolated from patients’ peripheral leukocyte
pellets of blood samples. The methods for the genotyping have
been previously described [29,30]. Approximately 10% of the
samples were also selected for retesting for quality control
purposes, and the repeated results were 100% concordant.
Statistical Analysis
The x
2 test was used to evaluate the differences in the
distributions of selected demographic characteristics, tobacco
smoking and alcohol drinking between HPV16
+ and HPV16
2
cases, and used the Student’s t test for comparison of mean values
of age between the two groups. Association of HPV16 positivity of
oropharyngeal cancer patients with variant genotypes of p53 and
p73 polymorphisms was estimated by computing the odds ratios
(ORs) and 95% confidence intervals (95% CIs). Both univariate
and multivariable logistic regression models were performed for
the analyses. Multivariable logistic regression models were fully
adjusted with age, sex, ethnicity, and smoking and alcohol status.
These variables were selected for adjustment after a stepwise
search strategy in developing such multivariable models. Former
smokers were defined as smokers who had quit smoking at least 1
year before presentation, and former smokers were grouped with
current smokers as ‘‘ever-smokers’’. ‘‘Never smokers’’ were defined
as those who had smoked fewer than 100 cigarettes in their
lifetime. ‘‘Drinkers’’ were defined as those who had at least one
alcoholic drink per week for at least 1 year, while ‘‘former
drinkers’’ were defined as those who had quit drinking alcoholic
beverages in this manner for at least 1 year before presentation.
Association was considered to be statistically significant for a two-
sided test set at p,0.05. Statistical Analysis System software
(Version 9.1; SAS Institute, Cary, NC) was used for all statistical
analyses.
Results
The p53 and p73 genotype data, demographic characteristics,
smoking status and drinking status of the patients are shown in
Table 1. The distribution of sex and smoking status was
significantly different between HPV16-positive and HPV16-
negative oropharyngeal cancer patients (P=0.010 for sex and
P=0.003 for tobacco smoking). There was no significant
difference in age between tumor HPV16-positive (median, 54
years; mean, 54.0 years; and range, 28–81 years) and tumor
HPV16-negative oropharyngeal cancer patients (median, 52 years;
mean, 54.9 years; and range, 30–83 years). Neither was in
ethnicity and alcohol drinking status between the two groups.
The results of genotype distributions and allele frequencies of
p73 and p53 in HPV16-positive and HPV16-negative patients are
summarized in Table 2. The AT and Pro variant alleles of p73
and p53 were significantly more common among HPV16-positive
patients (26.1% for p73 and 23.7% for p53) than among HPV16-
negative patients (16.5% for p73 and 15.2% for p53)( P=0.020 for
p73 and P=0.043 for p53), indicating that the AT and Pro alleles
may be associated with tumor HPV16-positivity among oropha-
ryngeal cancer patients. Compared with the wild-type GC/GC
homozygote, the combined GC/AT+AT/AT variant genotypes
p53 and p73 Variants and HPV Status
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ryngeal cancer (OR, 2.1, 95% CI, 1.2–3.8). Furthermore, the
dose-effect relationship between the number of the AT alleles and
the tumor HPV16-positive oropharyngeal cancer was statistically
significant (P=0.010). For p53 polymorphism, both Arg/Pro and
Pro/Pro genotypes were found to have no association with
HPV16-positive oropharyngeal tumors (OR 1.2, 95% CI 0.6–2.5;
and OR 1.1, 95% CI 0.1–9.1, respectively). whereas compared
with the p53 Arg/Arg homozygote, the combined Arg/Pro+Pro/
Pro variant genotypes were significantly associated with tumor
HPV16-positive oropharyngeal cancer (OR, 1.9, 95% CI, 1.1–
3.3).
No interaction effect between these two polymorphisms on
tumor HPV16 status in oropharyngeal cancer patients was
observed (Pint.=0.374), while the oropharyngeal cancer patients
with variant genotypes of both p53 and p73 polymorphisms were
more likely to have HPV16-positive tumors. Therefore, to evaluate
the association of tumor HPV16 status with combined risk
genotypes of both polymorphisms, the study subjects were
categorized into three main groups based on the level of
association of tumor HPV16 positivity with variant genotypes of
each polymorphism (Table 3): 1) the low-risk group (if subjects
with p53 Arg/Arg and p73 GC/GC genotypes); 2) the medium-
risk group (if subjects with p53 Arg/Arg and p73 AT carriers or
Table 1. Distribution of selected variables in patients with oropharyngeal cancer by tumor HPV16 status.
Variable HPV16
+ Patients (N=230) HPV16
2 Patients (N=79) P value
*
No. % No. %
Age
#50years 77 33.5 31 39.2 0.354
.50 years 153 66.5 48 60.8
Sex
Male 207 90.0 62 78.5 0.010
Female 23 10.0 17 21.5
Ethnicity
Non-Hispanic white 216 94.0 70 88.6 0.121
Others 14 6.0 9 11.4
Tobacco smoking
Ever 119 51.7 56 70.9 0.003
Never 111 48.3 23 29.1
Alcohol drinking
Ever 179 77.8 61 77.2 0.910
Never 51 22.2 18 22.8
*Two-sided x
2 test.
doi:10.1371/journal.pone.0035522.t001
Table 2. Association of tumor HPV16 positivity of patients with oropharyngeal cancer with p73 and p53 Genotypes.
HPV16
+ Patients (N=230) HPV16
2 Patients (N=79) Crude OR Adjusted OR
Genotypes No. % No. % (95% CI) (95% CI)
a
p73 G4C14-to-A4T14
GC/GC
b 123 53.5 55 69.6 1.0 1.0
GC/AT 94 40.9 22 27.9 1.9 (1.1–3.4) 2.1 (1.1–3.7)
AT/AT 13 5.6 2 2.5 2.9 (0.6–13.3) 3.0 (0.6–14.5)
Combined variant genotypes
GC/AT+AT/AT 107 46.5 24 30.4 2.0 (1.2–3.4) 2.1 (1.2–3.8)
p53 Arg/Pro
Arg/Arg
b 130 56.5 56 70.9 1.0 1.0
Arg/Pro 91 39.6 22 27.8 1.3 (0.6–2.7) 1.2 (0.6–2.5)
Pro/Pro 9 3.9 1 1.3 1.1 (0.1–10.5) 1.1 (0.1–9.1)
Combined variant genotypes
Arg/Pro+Pro/Pro 100 43.5 23 29.1 1.9 (1.1–3.2) 1.9 (1.1–3.3)
aAdjusted for age, sex, ethnicity, smoking and alcohol use in a logistic regression model.
bReference group.
doi:10.1371/journal.pone.0035522.t002
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group (if subjects with p53 Pro carriers and p73 AT carriers),
respectively. Compared with the low-risk group, both the medium-
risk and high-risk groups exhibited a significant association with
tumor HPV16 positivity (OR, 2.4, 95% CI, 1.3–4.2 and OR, 3.2,
95% CI, 1.4–7.4, respectively). The dose-effect relationship
between the combined p53 and p73 variant genotypes and tumor
HPV16 positivity in oropharyngeal cancer was also statistically
significant (p=0.001).
The stratified analyses by age, sex, ethnicity, smoking status,
and alcohol status are shown in Table 4, and the association was
further evaluated with adjustment for the aforementioned
variables. The association was more pronounced among patients
who were older, men, non-Hispanic white, never-smokers, and
ever drinkers. For example, compared with the low-risk group, the
high-risk group exhibited a greater association with HPV16-
positive tumor status among male patients (OR, 3.5, 95% CI, 1.4–
8.6) and in never smokers (adjusted OR, 5.0, 95% CI, 1.0–24.7) as
opposed to a non-significant association among female patients
(OR, 2.1, 95% CI, 0.1–30.0) and an OR of 3.0 in ever smokers
(OR, 3.0, 95% CI, 1.0–8.2). Furthermore, a significant dose-effect
relationship between combined p53 and p73 variant genotypes and
tumor HPV16 positivity in oropharyngeal cancer was also
observed among several subgroups, such as in patients who were
older, men, non-Hispanic white, and never smokers (p,0.01).
Discussion
We and others have previously assessed associations of these two
polymorphisms with HPV-associated SCCHN or their subgroups
in several studies [31–35], while these studies categorized HPV16
status of study patients based on serology or included mixed cancer
sites due to the unavailability of tumor status in our previous
studies [31,32,34,35]. These studies suggest that HPV tumor
positivity may have powerful prognostic effect on outcomes of
oropharyngeal cancer, whereas these results are not in agreement
with the findings of others [36–38]. It should be noted that other
prognostic variables, including patient demographics, tumor site
and stage, and treatment may also significantly affect the outcomes
of oropharyngeal cancer. Particularly, a later stage, nodal
involvement and advanced grade were frequently seen in HPV-
positive cancers [12]. Therefore, to guide treatment recommen-
dations for the future, the suggestion that HPV tumor positivity is
a favorable prognostic marker needs to be viewed critically given
that significant confounding is not controlled for a variety of
independent prognostic variables.
The data from this study suggest that variant genotypes of each
polymorphism may individually, and more likely jointly, influence
on tumor HPV16 status in oropharyngeal cancer and could be
potentially susceptible markers for the tumor HPV16-positive
patients. This study with tumor-based HPV16 status and a
homogenous subgroup of SCCHN patients would help more
accurately evaluate the associations between the p53 and p73
polymorphisms and tumor HPV16-positive oropharyngeal can-
cers. Although the precise mechanism by which these polymor-
phisms affect the tumor HPV16 status of oropharyngeal cancer
has not yet been clarified, there are some biologically plausible
explanations. Firstly, p53 and p73 proteins structurally have
similar domain structures and very high amino acid identities in
DNA-binding domain [39]. Functionally, these two proteins have
some common target genes, and may play similar roles in
regulation of several cellular activities such as cell cycle control,
DNA repair, and apoptosis [13–16]. Additionally, both p53 and
p73 can interact with HPV16 by being directly bound to and
subsequently degraded or inactivated by oncoprotein E6
[20,21,40], and p73 may compensate for the loss of p53 function
in some human malignancies. Furthermore, p73 can promote
apoptosis via the E2F-p73 pathway and inactivation of p73 by
oncogenic HPV16 E6 appears to be analogous to its inactivation
of p53 without the modulation of the DNA-binding activities
[28,41]. Finally, unlike p53, p73 is resistant to degradation by
HPV16 E6, can suppress cell growth, and induce apoptosis in
HPV16 E6-expressing cells [42]. It is our speculation that p53 and
p73 polymorphisms may be jointly associated with tumor HPV16
status in oropharyngeal cancer through interaction among HPV16
oncoprotein E6, p53 and p73.
Several studies have reported that p53 codon 72 and p73
G4C14-to-A4T14 polymorphisms were significantly associated
with risk of HPV16-associated squamous cell carcinoma of the
oropharynx [31–33]. Perrone, et al. found that p53 72RP
genotype may have a protective effect on risk of oropharyngeal
cancer, while the PP genotype is associated with HPV16-positive
tumors [33]. The discrepancy between these findings and our
current findings might be, at least in part, explained by following
several factors including differences in race, small sample sizes,
differences in study designs, and lack of detailed information on
smoking and alcohol use.
Stratified analyses have shown that association between
combined p53 and p73 variant genotypes and tumor HPV16
positivity in oropharyngeal cancer was more pronounced among
never-smoker patients. This result may provide additional support
for findings in several previous studies, in which it was reported
Table 3. Association of tumor HPV16 positivity of patients with oropharyngeal cancer with combined p73 and p53 variant
genotypes.
Combined p53 and p73
variant genotypes
a HPV16
+ Patients (N=230) HPV16
2 Patients (N=79) Crude OR (95% CI) Adj. OR (95% CI)
b
No. % No. %
Low-risk group 72 31.3 41 51.9 1.0 (ref.
c) 1.0 (ref.
c)
Medium-risk group 109 47.4 29 36.7 2.1 (1.2–3.8) 2.4 (1.3–4.2)
High-risk group 49 21.3 9 11.4 3.1 (1.4–7.0) 3.2 (1.4–7.4)
Trend test P=0.001 P=0.001
aLow-risk group: individuals with p53 Arg/Arg and p73 GC/GC genotypes; Medium-risk group: individuals with p53 Arg/Arg and p73 AT carriers or p53 Pro carriers and
p73 C/GC; and High-risk group: individuals with p53 Pro carriers and p73 AT carriers.
bORs were adjusted for age, sex, ethnicity, smoking, and alcohol use in a logistic regression model.
cReference group.
doi:10.1371/journal.pone.0035522.t003
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by HPV, while most nonoropharyngeal cancers were caused by
smoking and drinking [43,44]. As HPVs have evolved several
mechanisms to bypass immune recognition or killing, p53 and p73
polymorphisms possibly modulate the apoptotic capacity of the
host to clear cells infected with HPV through inflammation/
immune systems, which control the HPV clearance and escape of
immune surveillance, subsequently affecting the tumor HPV status
[45]. However, these hypotheses need to be tested in future
studies.
The oropharyngeal cancer patients who were moderate to
heavy drinkers were less likely to be tumor HPV-positive [3],
whereas association between tumor HPV16 positivity and
combined p53 and p73 variant genotypes in oropharyngeal
cancer were more evident in ever-drinkers and men in current
study (adjusted OR, 2.8, 95% CI, 1.1–6.9 for ever drinkers and
OR, 3.5, 95% CI, 1.4–8.6 for male patients), suggesting HPV16
infection may act synergistically with alcohol and/or tobacco
exposure, although nonsmokers/nondrinkers were more likely to
have HPV-positive oropharyngeal cancer than smokers/drinkers
[46]. In addition, ethanol consumption may synergize with p53
and p73 variants to increase susceptibility to HPV16 infection
through either suppression of immune responses or changes in
sexual behaviors. However, further analyses could not be
performed qualitatively as data on specificity, intensity and
duration of alcohol exposure were limited in this study. When
compared with the finding reported in another study [3], we
found that the association between HPV16 positivity and
combined p53 and p73 risk genotypes was of significance in old
patients. A simple explanation for the inconsistent findings
follows. Young patients may have strong immune response
generated against an HPV infection compared with old patients
and thus have strong ability of the host to clear cells infected with
HPV, less likely having HPV16-positive tumors. However, all
these hypotheses mentioned above need to be tested in future
large studies.
Strengths of this study include analysis of single tumor site
(only oropharyngeal cancer patients), HPV16 tumor status
instead of serology, and careful quality control in genotyping.
Our analysis among only oropharyngeal cancer patients mini-
mizes the issue of the confounding effect from mixed tumor sites,
and determination of HPV16 tumor status instead of serology
greatly improves classification of study patients and accuracy of
the association in this analysis. Although our study has such
several strengths, interpretation of our findings may be limited for
several main reasons. First, compared with HPV16-negative
cancer patients, HPV16-positive cancer patients have distinct
clinical characteristics, demographic variables and epidemiolog-
ical risk factors. Thus, it is difficult to match these factors in such
a study. However, in current analysis, our study was adjusted for
age, sex, ethnicity, tobacco smoking and alcohol drinking, and
the potential effect of confounding factors on this association
should be minimized. Second, the sample sizes in each stratum of
the analyses were relatively small, and our estimates of association
could be observed by chance. Third, misclassification of tumor
HPV16 status could occur due to the presence of lower copies of
HPV in some tumor cells [47]. Finally, our study was not
population-based case-control study design instead of a case-case
Table 4. Stratified analysis of associations between combined p73 and p53 variant genotypes and tumor HPV16 status among
oropharyngeal cancer patients.
Variables Adjusted OR (95% CI)
Low-Risk Group
a
OR
b
Medium-Risk
Group
a
OR
b, 95% CI
High-Risk
Group
a
OR
b, 95% CI Trend Test
CASE/CNTL
c CASE/CNTL
c CASE/CNTL
c
Total 72/41 1.0
d 109/29 2.4 (1.3–4.2) 49/9 3.2 (1.4–7.4) ,0.01
Age (years)
#50 27/12 1.0 32/14 1.3 (0.4–3.6) 18/5 2.1 (0.6–7.5) 0.285
.50 45/29 1.0 77/15 3.9 (1.8–8.3) 31/4 5.0 (1.5–16.0) ,0.01
Sex
Male 64/33 1.0 97/21 2.8 (1.4–5.4) 46/8 3.5 (1.4–8.6) 0.001
Female 8/8 1.0 12/8 1.4 (0.3–5.8) 3/1 2.1 (0.1–30.0) 0.546
Ethnicity
Non-Hispanic White 66/36 1.0 102/26 2.4 (1.3–4.5) 48/8 3.6 (1.5–8.7) ,0.01
Others 6/5 1.0 7/3 8.8 (0.5–146.0) 1/1 5.8 (0.1–291.2) 0.225
Smoking
Never 38/15 1.0 51/6 3.9 (1.3–11.5) 22/2 5.0 (1.0–24.7) 0.011
Ever 34/26 1.0 58/23 2.0 (0.9–4.1) 27/7 3.0 (1.0–8.2) 0.020
Alcohol
Never 17/9 1.0 23/8 2.4 (0.6–8.7) 11/1 6.1 (0.6–62.7) 0.080
Ever 55/32 1.0 86/21 2.6 (1.3–5.1) 38/8 2.8 (1.1–6.9) ,0.01
aLow-Risk group: individuals with p53 Arg/Arg and p73 GC/GC genotypes; Medium-Risk group: individuals with p53 Arg/Arg and p73 AT carriers or p53 Pro carriers and
p73 GC/GC; and High-Risk group: individuals with p53 Pro carriers and p73 AT carriers.
bORs were adjusted for age, sex, ethnicity, smoking status, and alcohol use in a logistic regression model.
cCASE/CNTL: HPV16
+/HPV16
2 patients.
dLow-risk group was used as the reference group.
doi:10.1371/journal.pone.0035522.t004
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the control group of tumor HPV16-negative patients may not
adequately represent the true prevalence of HPV 16 exposure in
the general population.
In conclusion, our study demonstrated that the combined
variant genotypes of p53 codon 72 and p73 G4C14-to-A4T14
polymorphisms individually, and more likely jointly, had a
significantly effect on tumor HPV16 status in patients with
oropharyngeal cancer, particularly in never-smoker patients.
However, further studies with larger sample sizes are needed to
verify our findings.
Acknowledgments
We gratefully acknowledge Angelique Siy for editing; Margaret Lung,
Liliana Mugartegui and Angeli Fairly for their help with patient
recruitment; and Li-E Wang for laboratory management.
Author Contributions
Conceived and designed the experiments: ZW EMS WG XS FZ LX QW
GL. Performed the experiments: ZW EMS WG XS FZ GL. Analyzed the
data: ZW EMS WG LX GL. Contributed reagents/materials/analysis
tools: EMS QW GL. Wrote the paper: ZW EMS WG LX QW GL.
References
1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK (1933) Head and neck
cancer. N Engl J Med 328: 184–194.
2. Dobrossy L (2005) Epidemiology of head and neck cancer: magnitude of the
problem. Cancer Metastasis Rev 24: 9–17.
3. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, et al. (2000)
Evidence for a causal association between human papillomavirus and a subset of
head and neck cancers. J Natl Cancer Inst 92: 709–720.
4. Koch WM, Lango M, Sewell D, Zahurak M, Sidransky D (1999) Head and neck
cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope
109: 1544–1551.
5. Haughey BH, Hinni ML, Salassa JR, Hayden RE, Grant DG, et al. (2011)
Transoral laser microsurgery as primary treatment for advanced-stage
oropharyngeal cancer: a United States multicenter study. Head Neck 33:
1683–1694.
6. Rich JT, Liu J, Haughey BH (2011) Swallowing function after transoral laser
microsurgery (TLM) 6 adjuvant therapy for advanced-stage oropharyngeal
cancer. Laryngoscope 121: 2381–2390.
7. Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, et al. (2008) Distinct risk
factor profiles for human papillomavirus type 16-positive and human
papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst
100: 407–420.
8. Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, et al. (2003)
Human papillomavirus infection as a prognostic factor in carcinomas of the oral
cavity and oropharynx. Int J Cancer 104: 336–344.
9. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E (2002)
Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of
relapse, and survival. Int J Cancer 89: 300–304.
10. Li W, Thompson CH, O’Brien CJ, McNeil EB, Scolyer RA, et al. (2003)
Human papillomavirus positivity predicts favourable outcome for squamous
carcinoma of the tonsil. Int J Cancer 106: 553–558.
11. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM (2001) Human
papillomavirus positive squamous cell carcinoma of the oropharynx: a
radiosensitive subgroup of head and neck carcinoma. Cancer 92: 805–813.
12. Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, et al. (2004)
Age, sexual behavior and human papillomavirus infection in oral cavity and
oropharyngeal cancers. Int J Cancer 108: 766–772.
13. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:
307–310.
14. Helton ES, Chen X (2000) p53 modulation of the DNA damage response. J Cell
Biochem 100: 883–896.
15. Jost CA, Marin MC, Kaelin WG (1997) p73 is a simian [correction of human]
p53-related protein that can induce apoptosis. Nature 389: 191–194.
16. Melino G, De Laurenzi V, Vousden KH (2002) p73: friend or foe in
tumorigenesis. Nat Rev Cancer 2: 605–615.
17. Fakhry C, Gillison ML (2006) Clinical implications of human papillomavirus in
head and neck cancers. J Clin Oncol 24: 2606–2611.
18. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, et al. (2003) Human
papillomavirus and oral cancer: the International Agency for Research on
Cancer multicenter study. J Natl Cancer Inst 95: 1772–1783.
19. Munger K, Howley PM (2002) Human papillomavirus immortalization and
transformation functions. Virus Res 89: 213–228.
20. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The
E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes
the degradation of p53. Cell 63: 1129–1136.
21. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6
and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination
of p53. Cell 75: 495–505.
22. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, et al. (1999) Two
polymorphic variants of wild-type p53 differ biochemically and biologically. Mol
Cell Biol 19: 1092–1100.
23. Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M (2003) The
codon 72 polymorphic variants of p53 have markedly different apoptotic
potential. Nat Genet 33: 357–365.
24. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, et al. (1998) Role of a
p53 polymorphism in the development of human papillomavirus-associated
cancer. Nature 393: 229–234.
25. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, et al. (1997)
Monoallelically expressed gene related to p53 at 1p36, a region frequently
deleted in neuroblastoma and other human cancers. Cell 90: 809–819.
26. Haber DA, Fearon ER (1998) The promise of cancer genetics. Lancet 351 Suppl
2: SII1–8.
27. Guan X, Sturgis EM, Lei D, Liu Z, Dahlstrom KR, et al. (2010) Association of
TGF-b1 Genetic Variants with HPV16-positive Oropharyngeal Cancer. Clin
Cancer Res 16: 1416–1422.
28. Park JS, Kim EJ, Lee JY, Sin HS, Namkoong SE, et al. (2001) Functional
inactivation of p73, a homolog of p53 tumor suppressor protein, by human
papillomavirus E6 proteins. Int J Cancer 91: 822–827.
29. Li G, Sturgis EM, Wang LE, Chamberlain RM, Amos CI, et al. (2004)
Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of
squamous cell carcinoma of the head and neck. Carcinogenesis 25: 1911–1916.
30. Li F, Sturgis EM, Zafereo M, Wei Q, Li G (2010) Association of p53 codon 72
polymorphism with risk of second primary malignancy in patients with
squamous cell carcinoma of the head and neck. Cancer 116: 2350–2359.
31. Ji X, Neumann AS, Sturgis EM, Wei Q, Li G (2008) p53 codon 72
polymorphism associated with risk of human papillomavirus-associated
squamous cell carcinoma of the oropharynx in never smokers. Carcinogenesis
29: 875–879.
32. Chen X, Sturgis EM, Etzel CJ, Wei Q, Li G (2008) p73 G4C14-to-A4T14
polymorphism and risk of human papillomavirus associated squamous cell
carcinoma of the oropharynx in never smokers and never drinkers. Cancer 113:
307–314.
33. Perrone F, Mariani L, Pastore E, Orsenigo M, Suardi S, et al. (2007) p53 codon
72 polymorphisms in human papillomavirus-negative and human papillomavi-
rus-positive squamous cell carcinomas of the oropharynx. Cancer 109:
2461–2465.
34. Chen X, Sturgis EM, El-Naggar AK, Wei Q, Li G (2008) Combined effects of
the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of
HPV16-associated oral cancer in never-smokers. Carcinogenesis 29: 2120–2125.
35. Ji X, Sturgis EM, Zhao C, Wei Q, Li G (2009) Association of p73 G4C14-to-
A4T14 polymorphism with human papillomavirus type 16 status in squamous
cell carcinoma of the head and neck in non-Hispanic Whites. Cancer 115:
1660–1668.
36. Pintos J, Franco EL, Black MJ, Bergeron J, Arella M (1999) Human
papillomavirus and prognoses of patients with cancers of the upper aerodigestive
tract. Cancer 85: 1903–1909.
37. Ba ´ez A, Almodo ´var JI, Cantor A, Celestin F, Cruz-Cruz L, et al. (2004) High
frequency of HPV16-associated head and neck squamous cell carcinoma in the
Puerto Rican population. Head Neck 26: 778–784.
38. Koskinen WJ, Chen RW, Leivo I, Ma ¨kitie A, Ba ¨ck L, et al. (2003) Prevalence
and physical status of human papillomavirus in squamous cell carcinomas of the
head and neck. Int J Cancer 107: 401–406.
39. Melino G, Lu X, Gasco M, Crook T, Knight RA (2003) Functional regulation of
p73 and p63: development and cancer. Trends Biochem Sci 28: 663–670.
40. Werness BA, Levine AJ, Howley PM (1990) Association of human papilloma-
virus types 16 and 18 E6 proteins with p53. Science 248: 76–79.
41. Phillips AC, Vousden KH (2001) E2F-1 induced apoptosis. Apoptosis 6:
173–182.
42. Das S, Somasundaram K (2006) Therapeutic potential of an adenovirus
expressing p73 beta, a p53 homologue, against human papillomavirus positive
cervical cancer in vitro and in vivo. Cancer Biol Ther 5: 210–217.
43. Dahlstrom KR, Adler-Storthz K, Etzel CJ, Wei Q, Strugis EM (2003) Human
papillomavirus type 16 infection and squamous cell carcinoma of the head and
neck in never-smokers: a matched pair analysis. Clin Cancer Res 9: 2620–2626.
44. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, et
al. (2006) Human papillomavirus as a risk factor for the increase in incidence of
tonsillar cancer. Int J Cancer 119: 2620–2623.
45. Favre A, Paoli D, Poletti M, Marzoli A, Giampalmo A, et al. (1986) The human
palatine tonsil studied from surgical specimens at all ages and in various
pathological conditions. 1. Morphological and structural analyses. Z Mikrosk
Anat Forsch 100: 7–33.
p53 and p73 Variants and HPV Status
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e3552246. Fouret P, Monceaux G, Temam S, Lacourreye L, St Guily JL (1997) Human
papillomavirus in head and neck squamous cell carcinomas in nonsmokers. Arch
Otolaryngol Head Neck Surg 123: 513–516.
47. Huang CC, Qiu JT, Kashima ML, Karman RJ, Wu TC (1998) Generation of
type-specific probes for the detection of single-copy human papillomavirus by a
novel in situ hybridization method. Mod Pathol 11: 971–977.
p53 and p73 Variants and HPV Status
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35522